Search
Ceritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalCeritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells … Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of
Synonyms: N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamidemRNA-1283
go.drugbank.com/drugs/DB22668ApprovedInvestigational[L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from … [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna.
Acetylcholine
go.drugbank.com/drugs/DB03128ApprovedInvestigationalIt is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications. … Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in
Synonyms: O-AcetylcholineBrinzolamide
go.drugbank.com/drugs/DB01194Approved[A2051] Brinzolamide was approved by the FDA in 1998 as a standalone product and in 2013 as a combination product with brimonidine tartrate. … Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase II (CA-II) inhibitor indicated to reduce ocular pressure in patients with ocular hypertension or open-angle glaucoma.
Selexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalSelexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary
Isoeugenol
go.drugbank.com/drugs/DB14188ApprovedIt is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278]. … Allergic reactivity to Isoeugenol may be identified with a patch test.
Ropinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIn 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.
Tramadol
go.drugbank.com/drugs/DB00193ApprovedInvestigationalTramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the … [A4269,A183842] Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Noax uno 100 mg Retardtabletten, TRAMADOL SANDOZ UNO 150MGMilnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalFurthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia [F3925], although other regional regulatory authorities like the EMA, among others, have not … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment
Categories: Analgesics, Non-Narcotic, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProtriptyline
go.drugbank.com/drugs/DB00344ApprovedIn non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. … The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission.
Synonyms: 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine, N-methyl-5H-dibenzo[a,d]cycloheptene-5-propanamineCategories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome